Latest Shionogi & Co. Ltd. Stories
FLORHAM PARK, N.J., March 30, 2015 /PRNewswire/ -- Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met
Oral presentation and nine posters presented at ICAAC WASHINGTON, Sept.
DUBLIN, May 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/78cbh2/global_pva_drugs)
FLORHAM PARK, N.J., May 9, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the publication in Pediatrics of data demonstrating the efficacy of non-stimulant KAPVAY(TM) (clonidine hydrochloride) extended-release tablets when combined with stimulant medications for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (6-17 years).
- Emitting flashes of light; glittering.